May 2010
Networked Insights Closes an Oversubscribed Series A Round
Networked Insights recently closed a $5 million Series A Preferred Stock Round led by the Kegonsa Seed Fund. Proceeds will support the scale-up of sales and client support to maximize the company's value for acquisition within 12 to 18 months.
Stealth Therapeutics Poised to Take First Product to Market
Stealth Therapeutics has successfully completed additional FDA testing of the Invisiport, its first product. As a result, Stealth is poised to begin selling the Invisiport once it receives the FDA's final decision in June.
January 2010
Networked Insights Launches New Software Version
Networked Insights recently released Social Sense 2.0, the latest version of its flagship software product. This product helps advertisers analyze social networking sites so they can conduct more effective marketing.
Stealth Therapeutics Plans Product Launch This Year
Since Peter Drumm joined Stealth Therapeutics, Inc. as CEO in March 2008, he has ushered the company's products through the FDA approval process; the company expects FDA approval for the Invisiport, its first product, by second quarter 2010. Following approval, Drumm will set his marketing plan in place and launch the sales campaign. Stealth is already building product inventory.
Kegonsa News
- Three Kegonsa Companies Selected as 2010 Wisconsin Companies to Watch
- Kegonsa Experiences First Portfolio Company Exit
- Kegonsa Named to Entrepreneur's VC Top 100
- Kegonsa Seed Fund Launched
